Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Alector, Inc.

Market Cap 19Cr 17Cr 16Cr 15Cr 28Cr 1.83TCr 28Cr 186.13Cr 72Cr 902.39Cr 73Cr 71Cr 3.13TCr P/E 2026 *
-2.04x
P/E 2027 * -2.73x
Enterprise Value -5.28Cr -4.61Cr -4.27Cr -3.99Cr -7.49Cr -498.58Cr -7.54Cr -51Cr -20Cr -245.41Cr -20Cr -19Cr -852.13Cr EV / Sales 2026 *
-7.71x
EV / Sales 2027 * -5.77x
Free-Float
87.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+12.18%
1 week+14.38%
Current month-18.98%
1 month-17.06%
3 months-15.05%
6 months+25.00%
Current year+12.18%
1 week 1.41
Extreme 1.41
1.77
1 month 1.41
Extreme 1.41
2.32
Current year 1.41
Extreme 1.41
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
43.32
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 01/05/2013
Director of Finance/CFO 53 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
17/06Free

Director

38,150 0.0344%
17/06Free

Director

38,150 0.0344%
17/06Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
+12.18%+14.38%+19.86%-76.57% 19Cr
+1.44%-1.25%+63.52%+114.88% 5.44TCr
+4.60%+3.02%+58.20%+47.16% 4.58TCr
-1.44%+0.39%-12.94%-19.24% 2.3TCr
-2.69%-2.10%-3.68%+379.00% 2.08TCr
+3.22%-0.84%+27.88%-34.00% 1.63TCr
+0.58%+1.08%+16.73%-38.06% 1.53TCr
-1.01%-2.30%+27.42%+171.92% 1.3TCr
+4.95%+11.70%+123.63%+252.19% 1.25TCr
+3.07%+0.14%+29.37% - 1.24TCr
Average +2.49%+3.15%+35.00%+88.59% 2.14TCr
Weighted average by Cap. +1.64%+1.50%+40.84%+99.74%

Financials

2026 *2027 *
Net sales 68.57L 59.78L 55.37L 51.83L 97.21L 65Cr 97.8L 6.57Cr 2.55Cr 32Cr 2.57Cr 2.52Cr 110.58Cr 2.29Cr 2Cr 1.85Cr 1.73Cr 3.24Cr 215.9Cr 3.26Cr 22Cr 8.5Cr 106.27Cr 8.59Cr 8.4Cr 369Cr
Net income -9.41Cr -8.21Cr -7.6Cr -7.11Cr -13Cr -888Cr -13Cr -90Cr -35Cr -437.09Cr -35Cr -35Cr -1.52TCr -9.66Cr -8.42Cr -7.8Cr -7.3Cr -14Cr -911.64Cr -14Cr -93Cr -36Cr -448.72Cr -36Cr -35Cr -1.56TCr
Net Debt -25Cr -22Cr -20Cr -19Cr -35Cr -2.33TCr -35Cr -236.75Cr -92Cr -1.15TCr -93Cr -91Cr -3.99TCr -33Cr -28Cr -26Cr -25Cr -46Cr -3.08TCr -47Cr -312.65Cr -121.17Cr -1.52TCr -122.51Cr -119.88Cr -5.26TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
18/26/18 1.750 $ +12.18% 11,08,447
17/26/17 1.560 $ +1.30% 4,96,015
16/26/16 1.540 $ +4.05% 7,12,030
15/26/15 1.480 $ -3.27% 6,29,572
12/26/12 1.530 $ -2.55% 2,63,831
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.750USD
Average target price
3.100USD
Spread / Average Target
+77.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!